



Xintela publishes results from glioblastoma antibody study

Lund, Sweden, March 12, 2021 - Xintela announces that the results of the company's preclinical glioblastoma study with function-blocking antibodies have today been published in the renowned international scientific journal *Cancers*. The publication shows, among other things, that antibodies directed to the company's target molecule integrin $\alpha 10\beta 1$ significantly reduce the growth of the aggressive and deadly brain tumor glioblastoma in an animal model.

Glioblastoma is the most common and most aggressive brain tumor form in adults and there is an enormous need for new and better treatment strategies. The published article demonstrates that function-blocking antibodies directed against the target molecule integrin $\alpha 10\beta 1$ significantly reduce the tumor volume of glioblastoma tumors in an animal model and that the antibodies inhibit glioblastoma cell growth, survival and migration (movement). The work has been carried out in collaboration with IVRS (In Vivo Research Services) in Lund. The results show that Xintela's targeting antibodies are a promising new strategy for the treatment of glioblastoma. Xintela has approved patents that protect integrin $\alpha 10\beta 1$ antibodies for the treatment of CNS tumors including glioblastoma.

*- It is very encouraging that our antibody results have now been published in the international scientific journal *Cancers*, a leading journal in oncology research. It is an important milestone for our oncology project in the development of a First-in-Class therapy for glioblastoma and other aggressive tumors and also for our discussions with potential partners and investors, says Xintela's CEO Evy Lundgren-Åkerlund.*

The publication:

Integrin $\alpha 10$ -Antibodies Reduce Glioblastoma Tumor Growth and Cell Migration. Katarzyna Chmielarska Masoumi, Xiaoli Huang, Wondossen Sime, Anna Mirkov, Matilda Munksgaard Thorén, Ramin Massoumi and Evy Lundgren-Åkerlund. *Cancers* **2021**, *13*, 1184. <https://doi.org/10.3390/cancers13051184>

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 15:30 CET on the 12th of March, 2021.

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK[®]. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM[®]) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.